ISLMF (InSilico Medicine Cayman TopCo) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo 5-Year EBITDA Growth Rate?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's EBITDA per Share for the three months ended in Dec. 2025 was $-4.20.

During the past 3 years, the average EBITDA Per Share Growth Rate was -123.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of InSilico Medicine Cayman TopCo was -123.60% per year. The lowest was -123.60% per year. And the median was -123.60% per year.

InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

InSilico Medicine Cayman TopCo 5-Year EBITDA Growth Rate Related Terms

ISLMF vs : 5-Year EBITDA Growth Rate Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InSilico Medicine Cayman TopCo 5-Year EBITDA Growth Rate vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate falls into.


ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
InSilico Medicine Cayman TopCo (ISLMF) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate too high?
InSilico Medicine Cayman TopCo's current 5-Year EBITDA Growth Rate is 0.00%. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate compare to ?
InSilico Medicine Cayman TopCo's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Software company?
A good 5-Year EBITDA Growth Rate depends on the Software industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price